Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.

Identifieur interne : 001634 ( Main/Exploration ); précédent : 001633; suivant : 001635

Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.

Auteurs : Hatem A. Elshabrawy [États-Unis] ; Jilao Fan ; Christine S. Haddad ; Kiira Ratia ; Christopher C. Broder ; Michael Caffrey ; Bellur S. Prabhakar

Source :

RBID : pubmed:24501399

Descripteurs français

English descriptors

Abstract

Severe acute respiratory syndrome coronavirus (SARS-CoV) and Ebola, Hendra, and Nipah viruses are members of different viral families and are known causative agents of fatal viral diseases. These viruses depend on cathepsin L for entry into their target cells. The viral glycoproteins need to be primed by protease cleavage, rendering them active for fusion with the host cell membrane. In this study, we developed a novel high-throughput screening assay based on peptides, derived from the glycoproteins of the aforementioned viruses, which contain the cathepsin L cleavage site. We screened a library of 5,000 small molecules and discovered a small molecule that can inhibit the cathepsin L cleavage of all viral peptides with minimal inhibition of cleavage of a host protein-derived peptide (pro-neuropeptide Y). The small molecule inhibited the entry of all pseudotyped viruses in vitro and the cleavage of SARS-CoV spike glycoprotein in an in vitro cleavage assay. In addition, the Hendra and Nipah virus fusion glycoproteins were not cleaved in the presence of the small molecule in a cell-based cleavage assay. Furthermore, we demonstrate that the small molecule is a mixed inhibitor of cathepsin L. Our broad-spectrum antiviral small molecule appears to be an ideal candidate for future optimization and development into a potent antiviral against SARS-CoV and Ebola, Hendra, and Nipah viruses.

DOI: 10.1128/JVI.03050-13
PubMed: 24501399


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.</title>
<author>
<name sortKey="Elshabrawy, Hatem A" sort="Elshabrawy, Hatem A" uniqKey="Elshabrawy H" first="Hatem A" last="Elshabrawy">Hatem A. Elshabrawy</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois</wicri:regionArea>
<placeName>
<region type="state">Illinois</region>
<settlement type="city">Chicago</settlement>
</placeName>
<orgName type="university">Université de l'Illinois à Chicago</orgName>
</affiliation>
</author>
<author>
<name sortKey="Fan, Jilao" sort="Fan, Jilao" uniqKey="Fan J" first="Jilao" last="Fan">Jilao Fan</name>
</author>
<author>
<name sortKey="Haddad, Christine S" sort="Haddad, Christine S" uniqKey="Haddad C" first="Christine S" last="Haddad">Christine S. Haddad</name>
</author>
<author>
<name sortKey="Ratia, Kiira" sort="Ratia, Kiira" uniqKey="Ratia K" first="Kiira" last="Ratia">Kiira Ratia</name>
</author>
<author>
<name sortKey="Broder, Christopher C" sort="Broder, Christopher C" uniqKey="Broder C" first="Christopher C" last="Broder">Christopher C. Broder</name>
</author>
<author>
<name sortKey="Caffrey, Michael" sort="Caffrey, Michael" uniqKey="Caffrey M" first="Michael" last="Caffrey">Michael Caffrey</name>
</author>
<author>
<name sortKey="Prabhakar, Bellur S" sort="Prabhakar, Bellur S" uniqKey="Prabhakar B" first="Bellur S" last="Prabhakar">Bellur S. Prabhakar</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24501399</idno>
<idno type="pmid">24501399</idno>
<idno type="doi">10.1128/JVI.03050-13</idno>
<idno type="wicri:Area/PubMed/Corpus">001055</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001055</idno>
<idno type="wicri:Area/PubMed/Curation">001055</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001055</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000F84</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F84</idno>
<idno type="wicri:Area/Ncbi/Merge">002823</idno>
<idno type="wicri:Area/Ncbi/Curation">002823</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002823</idno>
<idno type="wicri:Area/Main/Merge">001639</idno>
<idno type="wicri:Area/Main/Curation">001634</idno>
<idno type="wicri:Area/Main/Exploration">001634</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.</title>
<author>
<name sortKey="Elshabrawy, Hatem A" sort="Elshabrawy, Hatem A" uniqKey="Elshabrawy H" first="Hatem A" last="Elshabrawy">Hatem A. Elshabrawy</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois</wicri:regionArea>
<placeName>
<region type="state">Illinois</region>
<settlement type="city">Chicago</settlement>
</placeName>
<orgName type="university">Université de l'Illinois à Chicago</orgName>
</affiliation>
</author>
<author>
<name sortKey="Fan, Jilao" sort="Fan, Jilao" uniqKey="Fan J" first="Jilao" last="Fan">Jilao Fan</name>
</author>
<author>
<name sortKey="Haddad, Christine S" sort="Haddad, Christine S" uniqKey="Haddad C" first="Christine S" last="Haddad">Christine S. Haddad</name>
</author>
<author>
<name sortKey="Ratia, Kiira" sort="Ratia, Kiira" uniqKey="Ratia K" first="Kiira" last="Ratia">Kiira Ratia</name>
</author>
<author>
<name sortKey="Broder, Christopher C" sort="Broder, Christopher C" uniqKey="Broder C" first="Christopher C" last="Broder">Christopher C. Broder</name>
</author>
<author>
<name sortKey="Caffrey, Michael" sort="Caffrey, Michael" uniqKey="Caffrey M" first="Michael" last="Caffrey">Michael Caffrey</name>
</author>
<author>
<name sortKey="Prabhakar, Bellur S" sort="Prabhakar, Bellur S" uniqKey="Prabhakar B" first="Bellur S" last="Prabhakar">Bellur S. Prabhakar</name>
</author>
</analytic>
<series>
<title level="j">Journal of virology</title>
<idno type="eISSN">1098-5514</idno>
<imprint>
<date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antiviral Agents (pharmacology)</term>
<term>Cathepsin L (metabolism)</term>
<term>Drug Evaluation, Preclinical (methods)</term>
<term>Ebolavirus (drug effects)</term>
<term>Ebolavirus (metabolism)</term>
<term>Hendra Virus (drug effects)</term>
<term>Hendra Virus (metabolism)</term>
<term>High-Throughput Screening Assays (methods)</term>
<term>Humans</term>
<term>Nipah Virus (drug effects)</term>
<term>Nipah Virus (metabolism)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (metabolism)</term>
<term>Small Molecule Libraries (pharmacology)</term>
<term>Viral Envelope Proteins (metabolism)</term>
<term>Virus Diseases (enzymology)</term>
<term>Virus Diseases (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Antiviraux (pharmacologie)</term>
<term>Bibliothèques de petites molécules (pharmacologie)</term>
<term>Cathepsine L (métabolisme)</term>
<term>Ebolavirus ()</term>
<term>Ebolavirus (métabolisme)</term>
<term>Humains</term>
<term>Maladies virales (enzymologie)</term>
<term>Maladies virales (virologie)</term>
<term>Protéines de l'enveloppe virale (métabolisme)</term>
<term>Tests de criblage à haut débit ()</term>
<term>Virus Hendra ()</term>
<term>Virus Hendra (métabolisme)</term>
<term>Virus Nipah ()</term>
<term>Virus Nipah (métabolisme)</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (métabolisme)</term>
<term>Évaluation préclinique de médicament ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Cathepsin L</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Antiviral Agents</term>
<term>Small Molecule Libraries</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Ebolavirus</term>
<term>Hendra Virus</term>
<term>Nipah Virus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr">
<term>Maladies virales</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en">
<term>Virus Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Ebolavirus</term>
<term>Hendra Virus</term>
<term>Nipah Virus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Drug Evaluation, Preclinical</term>
<term>High-Throughput Screening Assays</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Cathepsine L</term>
<term>Ebolavirus</term>
<term>Protéines de l'enveloppe virale</term>
<term>Virus Hendra</term>
<term>Virus Nipah</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Antiviraux</term>
<term>Bibliothèques de petites molécules</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr">
<term>Maladies virales</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en">
<term>Virus Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Ebolavirus</term>
<term>Humains</term>
<term>Tests de criblage à haut débit</term>
<term>Virus Hendra</term>
<term>Virus Nipah</term>
<term>Virus du SRAS</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Severe acute respiratory syndrome coronavirus (SARS-CoV) and Ebola, Hendra, and Nipah viruses are members of different viral families and are known causative agents of fatal viral diseases. These viruses depend on cathepsin L for entry into their target cells. The viral glycoproteins need to be primed by protease cleavage, rendering them active for fusion with the host cell membrane. In this study, we developed a novel high-throughput screening assay based on peptides, derived from the glycoproteins of the aforementioned viruses, which contain the cathepsin L cleavage site. We screened a library of 5,000 small molecules and discovered a small molecule that can inhibit the cathepsin L cleavage of all viral peptides with minimal inhibition of cleavage of a host protein-derived peptide (pro-neuropeptide Y). The small molecule inhibited the entry of all pseudotyped viruses in vitro and the cleavage of SARS-CoV spike glycoprotein in an in vitro cleavage assay. In addition, the Hendra and Nipah virus fusion glycoproteins were not cleaved in the presence of the small molecule in a cell-based cleavage assay. Furthermore, we demonstrate that the small molecule is a mixed inhibitor of cathepsin L. Our broad-spectrum antiviral small molecule appears to be an ideal candidate for future optimization and development into a potent antiviral against SARS-CoV and Ebola, Hendra, and Nipah viruses.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Illinois</li>
</region>
<settlement>
<li>Chicago</li>
</settlement>
<orgName>
<li>Université de l'Illinois à Chicago</li>
</orgName>
</list>
<tree>
<noCountry>
<name sortKey="Broder, Christopher C" sort="Broder, Christopher C" uniqKey="Broder C" first="Christopher C" last="Broder">Christopher C. Broder</name>
<name sortKey="Caffrey, Michael" sort="Caffrey, Michael" uniqKey="Caffrey M" first="Michael" last="Caffrey">Michael Caffrey</name>
<name sortKey="Fan, Jilao" sort="Fan, Jilao" uniqKey="Fan J" first="Jilao" last="Fan">Jilao Fan</name>
<name sortKey="Haddad, Christine S" sort="Haddad, Christine S" uniqKey="Haddad C" first="Christine S" last="Haddad">Christine S. Haddad</name>
<name sortKey="Prabhakar, Bellur S" sort="Prabhakar, Bellur S" uniqKey="Prabhakar B" first="Bellur S" last="Prabhakar">Bellur S. Prabhakar</name>
<name sortKey="Ratia, Kiira" sort="Ratia, Kiira" uniqKey="Ratia K" first="Kiira" last="Ratia">Kiira Ratia</name>
</noCountry>
<country name="États-Unis">
<region name="Illinois">
<name sortKey="Elshabrawy, Hatem A" sort="Elshabrawy, Hatem A" uniqKey="Elshabrawy H" first="Hatem A" last="Elshabrawy">Hatem A. Elshabrawy</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001634 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001634 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:24501399
   |texte=   Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:24501399" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021